Is Keros Therapeutics, Inc. Common Stock a growth stock? A data-driven read on its earnings momentum, price leadership, and demand, scored against every US stock from SEC filings and daily prices, and re-ranked after every close.
Not right now by CANSLIMAs of the 2026-07-28 close, KROS scores 7 out of 99 on our growth-stock rating, a weak growth-stock profile. That ranks it 4580th of 4,892 rated US stocks, the top 94% of the market.
Its strongest trait is S (supply & demand) at 51, and its weakest is A (annual earnings growth) at 0. KROS clears 0 of the six core growth traits we score per stock; the seventh, overall market direction, is judged market-wide.
On price, KROS carries a lagging Relative Strength rating of 18, meaning it has outperformed about 18% of the market over the past year.
Underneath the score: quarterly earnings down 133% year over year, sales down 100%, trading 54% below its 52-week high.
The six traits that separate real growth stocks from the rest: earnings, price leadership, and demand. Each is scored 1–99 against the whole US market. We compute them with the CANSLIM method, double-weighting earnings and relative strength.
| C | Current quarterly earnings most recent EPS growth vs. a year ago |
9 |
| A | Annual earnings growth multi-year earnings trend |
0 |
| N | New highs & catalysts proximity to new 52-week highs |
8 |
| S | Supply & demand volume behind the move vs. share supply |
51 |
| L | Leader or laggard Relative Strength within its group |
26 |
| I | Institutional sponsorship fund accumulation and 13F ownership |
29 |
On today’s data KROS does not clear the growth-stock bar CANSLIM sets. Scores are re-computed after every close, so this can change.
The stocks ranking above KROS today, the growth leaders you’d weigh against it.
Where KROS sits in its base, its 52-week path, and the trait trend over the past year.
Every US stock scored on the traits that define a growth stock and re-ranked after each close, with the top ranks, the full trait breakdown, and today’s market read.
Open the app, free through September 1Not right now by CANSLIM. On today’s data KROS does not clear the growth-stock bar CANSLIM sets. Scores are re-computed after every close, so this can change.
Keros Therapeutics, Inc. Common Stock (KROS) scores 7 out of 99 on our growth-stock rating as of the 2026-07-28 close, ranking 4580th of 4,892 rated US stocks.
KROS's most recent quarterly earnings were down about 133% year over year, with sales down 100%.
KROS has a Relative Strength rating of 18, meaning it has outperformed roughly 18% of the US market over the trailing year.
Create a free Growth Stock Analyzer account to see where KROS ranks against every US stock, the stronger growth stocks to weigh against it, and its full price and earnings history.
Want the method behind the score? Read how we grade growth stocks with CANSLIM.